Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
These accolades highlight our unwavering commitment to maintaining the highest safety standards
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Subscribe To Our Newsletter & Stay Updated
